HIGHLIGHTS
- who: HCV and colleagues from the University of Oxford, Oxford , BN, UK have published the paper: ClinicoEconomics and Outcomes Research press, in the Journal: (JOURNAL)
- what: This study investigates the costs and benefits associated with (a) treating now using the high-cost patented drug and_(b) postponing treatment until release of the lower-cost generic drugs with reference to the ICER. The mathematical framework in this study has been applied to hepatitis_C as a test case comparing two treatment scenarios: a baseline case where all individuals are treated with patented drugs before switching to generic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.